These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 26042196

  • 21. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.
    Matovu E, Enyaru JC, Legros D, Schmid C, Seebeck T, Kaminsky R.
    Trop Med Int Health; 2001 May; 6(5):407-11. PubMed ID: 11348535
    [Abstract] [Full Text] [Related]

  • 22. Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes.
    de Koning HP.
    Trends Parasitol; 2008 Aug; 24(8):345-9. PubMed ID: 18599351
    [Abstract] [Full Text] [Related]

  • 23. Transport proteins determine drug sensitivity and resistance in a protozoan parasite, Trypanosoma brucei.
    Munday JC, Settimo L, de Koning HP.
    Front Pharmacol; 2015 Aug; 6():32. PubMed ID: 25814953
    [Abstract] [Full Text] [Related]

  • 24. Comparison of the in vitro drug sensitivity of Trypanosoma brucei gambiense strains from West and Central Africa isolated in the periods 1960-1995 and 1999-2004.
    Likeufack AC, Brun R, Fomena A, Truc P.
    Acta Trop; 2006 Nov; 100(1-2):11-6. PubMed ID: 17078916
    [Abstract] [Full Text] [Related]

  • 25. Current chemotherapy of human African trypanosomiasis.
    Docampo R, Moreno SN.
    Parasitol Res; 2003 Jun; 90 Supp 1():S10-3. PubMed ID: 12811544
    [Abstract] [Full Text] [Related]

  • 26. Differential virulence of Trypanosoma brucei rhodesiense isolates does not influence the outcome of treatment with anti-trypanosomal drugs in the mouse model.
    Ndung'u K, Murilla GA, Thuita JK, Ngae GN, Auma JE, Gitonga PK, Thungu DK, Kurgat RK, Chemuliti JK, Mdachi RE.
    PLoS One; 2020 Jun; 15(11):e0229060. PubMed ID: 33151938
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO).
    Iten M, Matovu E, Brun R, Kaminsky R.
    Trop Med Parasitol; 1995 Sep; 46(3):190-4. PubMed ID: 8533023
    [Abstract] [Full Text] [Related]

  • 29. Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001.
    Pépin J, Mpia B.
    Emerg Infect Dis; 2005 Jun; 11(6):921-7. PubMed ID: 15963288
    [Abstract] [Full Text] [Related]

  • 30. Detection of mutant P2 adenosine transporter (TbAT1) gene in Trypanosoma brucei gambiense isolates from northwest Uganda using allele-specific polymerase chain reaction.
    Nerima B, Matovu E, Lubega GW, Enyaru JC.
    Trop Med Int Health; 2007 Nov; 12(11):1361-8. PubMed ID: 18045263
    [Abstract] [Full Text] [Related]

  • 31. Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei.
    Matovu E, Stewart ML, Geiser F, Brun R, Mäser P, Wallace LJ, Burchmore RJ, Enyaru JC, Barrett MP, Kaminsky R, Seebeck T, de Koning HP.
    Eukaryot Cell; 2003 Oct; 2(5):1003-8. PubMed ID: 14555482
    [Abstract] [Full Text] [Related]

  • 32. Trypanosoma brucei: lack of cross-resistance to melarsoprol in vitro by cymelarsan-resistant parasites.
    Scott AG, Tait A, Turner CM.
    Exp Parasitol; 1997 Jul; 86(3):181-90. PubMed ID: 9225768
    [Abstract] [Full Text] [Related]

  • 33. Drug transport and drug resistance in African trypanosomes.
    Mäser P, Lüscher A, Kaminsky R.
    Drug Resist Updat; 2003 Oct; 6(5):281-90. PubMed ID: 14643298
    [Abstract] [Full Text] [Related]

  • 34. Structural insights into drug transport by an aquaglyceroporin.
    Chen W, Zou R, Mei Y, Li J, Xuan Y, Cui B, Zou J, Wang J, Lin S, Zhang Z, Wang C.
    Nat Commun; 2024 May 11; 15(1):3985. PubMed ID: 38734677
    [Abstract] [Full Text] [Related]

  • 35. Arsenic and old taxa: subspeciation and drug sensitivity in Trypanosoma brucei.
    Dukes P.
    Trans R Soc Trop Med Hyg; 1984 May 11; 78(6):711-25. PubMed ID: 6241967
    [Abstract] [Full Text] [Related]

  • 36. A Trypanosoma brucei ORFeome-Based Gain-of-Function Library Identifies Genes That Promote Survival during Melarsoprol Treatment.
    Carter M, Gomez S, Gritz S, Larson S, Silva-Herzog E, Kim HS, Schulz D, Hovel-Miner G.
    mSphere; 2020 Oct 07; 5(5):. PubMed ID: 33028684
    [Abstract] [Full Text] [Related]

  • 37. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review).
    Gehrig S, Efferth T.
    Int J Mol Med; 2008 Oct 07; 22(4):411-9. PubMed ID: 18813846
    [Abstract] [Full Text] [Related]

  • 38. Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness.
    Pepin J, Milord F, Guern C, Schechter PJ.
    Lancet; 1987 Dec 19; 2(8573):1431-3. PubMed ID: 2891995
    [Abstract] [Full Text] [Related]

  • 39. Clinical presentation and treatment outcome of sleeping sickness in Sudanese pre-school children.
    Eperon G, Schmid C, Loutan L, Chappuis F.
    Acta Trop; 2007 Jan 19; 101(1):31-9. PubMed ID: 17207760
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of trypanocidal activity of combinations of anti-sleeping sickness drugs with cysteine protease inhibitors.
    Steverding D.
    Exp Parasitol; 2015 Jan 19; 151-152():28-33. PubMed ID: 25662707
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.